Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Quarterly results
Apyx Medical Corp (APYX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook Advanced Energy Sales increased 40% year-over-year in Q2"
05/11/2023 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook"
03/16/2023 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results&#59; Introduces Full Year 2023 Financial Outlook"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results&#59; Introduces Full Year 2022 Financial Outlook Advanced Energy Sales increased 52% year-over-year in Q4&#59; up 94% year-over-year in 2021"
11/12/2021 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 88% year-over-year in Q3"
05/12/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports Third Quarter 2020 Financial Results"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $4.4 million in Q1, up 66% year-over-year CLEARWATER, FL — - Apyx Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma ® , a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March 31, 2019. First Quarter 2019 Financial Summary:"
11/01/2018 8-K Quarterly results
Docs: "BVX__2018.11.01"
08/01/2018 8-K Quarterly results
Docs: "BVX__2018.08.01"
05/14/2018 8-K Quarterly results
Docs: "BVX__2018.05.14"
03/12/2018 8-K Quarterly results
Docs: "BVX__2018.03.12"
11/02/2017 8-K Quarterly results
Docs: "BVX__2017.11.02"
08/02/2017 8-K Quarterly results
Docs: "BVX__2017.08.02"
05/15/2017 8-K Quarterly results
Docs: "BVX__2017.05.15"
03/09/2017 8-K Form 8-K - Current report
08/01/2016 8-K Quarterly results
Docs: "BOVIE MEDICAL CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2016 AND 2015 Three Months Ended Six Months Ended June 30, June 30, 2016 2015 2016 2015 Sales $ 9,295 $ 7,274 $ 17,070 $ 13,402 Cost of sales 4,595 4,134 9,048 7,588 Gross profit 4,700 3,140 8,022 5,814 Other costs and expenses: Research and development 592 505 1,259 951 Professional services 396 313 753 644 Salaries and related costs 2,200 1,868 4,300 3,821 Selling, general and administrative 2,022 2,002 4,213 4,219 Total other costs and expenses 5,210 4,688 10,525 9,635 Loss from operations Interest expense, net Change in fair value of liabilities, net 41 90 128 1,534 Total other income , net 51 40 1,454 Loss before income taxes Income tax benefit, net -- -- -- Net loss $ $ ..."
05/11/2016 8-K Quarterly results
Docs: "BOVIE MEDICAL CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND 2015 Three Months Ended March 31, 2016 2015 Sales $ 7,775 $ 6,128 Cost of sales 4,452 3,454 Gross profit 3,323 2,674 Other costs and expenses: Research and development 668 446 Professional services 357 331 Salaries and related costs 2,100 1,952 Selling, general and administrative 2,191 2,217 Total other costs and expenses 5,316 4,946 Loss from operations Interest expense, net Change in fair value of liabilities, net 87 1,444 Total other expense, net 49 1,404 Loss before income taxes Income tax expense -- Net loss $ $ Accretion on convertible preferred stock -- Deemed dividend on conversion of warrants and Series A preferred stock to Series B convertible preferred stock -- 13,95..."
03/18/2016 8-K Quarterly results
Docs: "BOVIE MEDICAL CORPORATION REPORTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy